- Home
- WOOF vs KURA Comparison
WOOF vs KURA Comparison
Compare WOOF & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | KURA |
|---|---|---|
| Founded | 1965 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 762.1M | 841.6M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | WOOF | KURA |
|---|---|---|
| Price | $2.77 | $9.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $4.06 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,961,467,000.00 | $67,482,000.00 |
| Revenue This Year | $2.64 | $28.28 |
| Revenue Next Year | $1.55 | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $2.24 | $5.45 |
| 52 Week High | $4.19 | $12.49 |
Technical Indicators
Market Signals| Indicator | WOOF | KURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.